Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ashok Nigalaye Insider Profile
4 Followers
Ashok Nigalaye, Director at Elite Pharmaceuticals, holds 40.44M shares in Elite Pharmaceuticals (Ticker: ELTP). Most recently, Ashok Nigalaye Bought $2,000,000 shares of Elite Pharmaceuticals on May 21, 2015 for an estimated value of 120.00K.
Profitable Transactions
5 out of 8 Profitable Transactions
Average Return
-50.50%
Average return per transaction
Time Frame
Compare to
Insider Roles
Director
Roles that Ashok Nigalaye holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Jan 08, 2015 - Jan 08, 2016
Return:+61.10%
The most profitable trade made by Ashok Nigalaye
Ashok Nigalaye's Trading History
List of latest transactions for each holding click on a transaction to see Ashok Nigalaye's performance on stock
You May Also Like
Ashok Nigalaye insider profile FAQ
What is the percentage of profitable transactions made by Ashok Nigalaye?
The percentage of profitable transactions made by Ashok Nigalaye is 63%.
What is the average return per transaction made by Ashok Nigalaye?
The average return per transaction made by Ashok Nigalaye is -50.50%.
What stocks does Ashok Nigalaye hold?
Ashok Nigalaye holds: ELTP stocks.
What was Ashok Nigalaye’s latest transaction?
Ashok Nigalaye latest transaction was an Informative Buy of $120.00K.
What was Ashok Nigalaye's most profitable transaction?
Ashok Nigalaye’s most profitable transaction was an Informative Buy of ELTP stock on January 8, 2015. The return on the trade was 61.10%.
What is Ashok Nigalaye's role in Elite Pharmaceuticals?
Ashok Nigalaye's role in Elite Pharmaceuticals is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.